These results provide evidence that p53 restrains the tumorigenic features of CSCs by modulating the expression of CSC-specific genes and suggest that CD133 could be a potential target for tumor inhibition in highly tumorigenic cancers in which p53 function is impaired. This evidence concerns the gene TP53 and neoplasm.